Dose limiting toxicities previously observed with administration of KPT-330, including weight loss and anorexia, were not seen in this study, supporting further evaluation of standard chemotherapy combined XPO1 inhibitors such as KPT-335 [20]. The gene discussed is XPO1; the disease is Anorexia.